首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Flemingia macrophyllaExtract Ameliorates Experimental Osteoporosis in Ovariectomized Rats
【24h】

Flemingia macrophyllaExtract Ameliorates Experimental Osteoporosis in Ovariectomized Rats

机译:大叶火烈鸟提取物可改善去卵巢大鼠的实验性骨质疏松症

获取原文
           

摘要

Flemingia macrophylla(Leguminosae), a native plant of Taiwan, is used as folk medicine. Anin vitrostudy showed that a 75% ethanolic extract ofF. macrophylla(FME) inhibited osteoclast differentiation of cultured rat bone marrow cells, and the active component, lespedezaflavanone A (LDF-A), was isolated. It was found that oral administration of FME for 13 weeks suppressed bone loss in ovariectomized rats, an experimental model of osteoporosis. In addition, FME decreased urinary deoxypyridinoline concentrations but did not inhibit serum alkaline phosphatase activities, indicating that it ameliorated bone loss via inhibition of bone resorption. These results suggest that FME may represent a useful remedy for the treatment of bone resorption diseases, such as osteoporosis. In addition, LDF-A could be used as a marker compound to control the quality of FME.
机译:台湾本土植物大叶火烈鸟(Flemingia macrophylla)用作民间药。体外研究表明,乙醇提取率为75%。大叶菊(FME)抑制培养的大鼠骨髓细胞的破骨细胞分化,并分离出有效成分莱斯佩达黄烷酮A(LDF-A)。已经发现,口服FME 13周可抑制卵巢切除大鼠的骨质流失,这是骨质疏松症的实验模型。此外,FME降低了尿中的脱氧吡啶并啉浓度,但没有抑制血清碱性磷酸酶活性,表明它通过抑制骨吸收改善了骨质流失。这些结果表明,FME可能代表治疗骨吸收性疾病(如骨质疏松症)的有用方法。此外,LDF-A可用作标记化合物,以控制FME的质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号